Safety and Immunogenicity of a Gag-Pol Candidate HIV-1 DNA Vaccine Administered by a Needle-Free Device in HIV-1–Seronegative Subjects

OBJECTIVE: To evaluate the safety and immunogenicity of a candidate HIV DNA vaccine administered using a needle-free device. DESIGN: In this phase 1, dose escalation, double-blind, placebo-controlled clinical trial, 21 healthy adults were randomized to receive placebo or 0.5, 1.5, or 4 mg of a singl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tavel, Jorge A., Martin, Julie E., Kelly, Grace G., Enama, Mary E., Shen, Jean M., Gomez, Phillip L., Andrews, Charla A., Koup, Richard A., Bailer, Robert T., Stein, Judy A., Roederer, Mario, Nabel, Gary J., Graham, Barney S.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2007
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2365751/
https://ncbi.nlm.nih.gov/pubmed/17325604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e3180417cb6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares